Valneva SE (VLA.PA)

4,6300 -0,1660 (-3,46%) Al 06:35PM CEST. Mercato aperto.

Valneva SE

6 rue Alain Bombard
Saint-Herblain 44800
France
33 2 28 07 37 10
https://valneva.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Thomas Lingelbach	Chairman of the Management Board, Pres & CEO	769,14k	N/D	1963
Mr. Franck Grimaud MBA	Director Gen., Chief Bus. Officer & Member of Management Board	482,35k	N/D	1967
Mr. Frederic Jacotot	VP of Legal & IP, Gen. Counsel, Corp. Sec. and Member of Management Board	378,59k	N/D	1965
Dr. Juan-Carlos Jaramillo M.D.	Chief Medical Officer & Member of the Management Board	527,17k	N/D	1972
Mr. Peter Buhler	CFO & Management Board Member	N/D	N/D	1971
Mr. Perry Celentano	Interim Chief Operating Officer	N/D	N/D	N/D
Ms. Dipal Patel	Chief Commercial Officer & Member of Management Board	N/D	N/D	N/D
Mr. Joshua Drumm Ph.D.	VP of Investor Relations	N/D	N/D	N/D
Ms. Laetitia Bachelot-Fontaine	VP of Global Communications & European Investor Relations	N/D	N/D	N/D
Mr. Gerald Strohmaier	VP of Human Resource	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.

Governance aziendale

L'ISS Governance QualityScore di Valneva SE al 1 marzo 2023 è 10. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 9; diritti degli azionisti: 6; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.